Abstract
BackgroundPoly (ADP-ribose) polymerase inhibitors have transformed the management landscape for patients with ovarian cancer, demonstrating remarkable improvements in progression-free survival and overall survival. Unfortunately, most relapses are due to an...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have